版本:
中国

最新动态: 浙江华海药业股份有限公司 (600521.SS)

600521.SS ( 上海证券交易所 )

15.89CNY
23 Aug 2019
涨跌 (%)

¥0.31 (+1.99%)
收盘
¥15.58
开盘
¥15.59
当日最高
¥16.13
当日最低
¥15.35
成交量
12,719,328
平均成交量
11,548,712
52 周最高
¥22.20
52 周最低
¥9.80

最新动态 (Source: Significant Developments)

European Medicines Agency Says EU Authorities Placing Zheijiang Huahai Under Increased Supervision
2018年 10月 15日 星期一 23:36 BJT 

Oct 15 (Reuters) - European Medicines Agency::EUROPEAN MEDICINES AGENCY - EU AUTHORITIES ARE PLACING THE CHINESE COMPANY ZHEIJIANG HUAHAI UNDER INCREASED SUPERVISION.EMA SAYS INSPECTION FINDINGS INCLUDED DEFICIENCIES IN THE WAY ZHEIJIANG HUAHAI INVESTIGATED IMPURITIES IN ITS VALSARTAN PRODUCTS.EUROPEAN MEDICINES AGENCY SAYS AUROBINDO PHARMA STOPPED FROM SUPPLYING IRBESARTAN TO THE EU.EMA SAYS AUTHORITIES IN EU CURRENTLY CONSIDERING WHETHER TO RECALL MEDICINES CONTAINING AUROBINDO PHARMA’S IRBESARTAN FROM PHARMACIES AS A PRECAUTION.EMA SAYS MARKETING AUTHORISATION HOLDERS FOR EU MEDICINES TO BE REQUIRED TO PERFORM MORE TESTS ON ALL ACTIVE SUBSTANCES SUPPLIED BY ZHEJIANG HUAHAI.EMA- PLACING ZHEIJIANG HUAHAI UNDER INCREASED SUPERVISION AFTER INSPECTIONS SHOWED WEAKNESSES IN QUALITY MANAGEMENT AT ITS CHUANNAN SITE IN LINHAI.  全文

Health Canada Finds Zhejiang Huahai Pharmaceuticals Site Non-Compliant With Requirements For Manufacture Of Drug Ingredients
2018年 10月 2日 星期二 23:11 BJT 

Oct 2 (Reuters) - Health Canada::HEALTH CANADA - FINDS ZHEJIANG HUAHAI PHARMACEUTICALS SITE NON-COMPLIANT WITH REQUIREMENTS FOR MANUFACTURE OF DRUG INGREDIENTS.HEALTH CANADA - DECISION BASED ON REVIEW OF INFORMATION FROM RECENT INSPECTION CONDUCTED BY U.S. FOOD AND DRUG ADMINISTRATION.HEALTH CANADA- NON-COMPLIANT RATING INCLUDES ASSESSING POSSIBLE EFFECTS ON DRUG SUPPLY AND WHETHER MEASURES MAY BE NEEDED TO MITIGATE SUPPLY CONCERNS.HEALTH CANADA - NO PRODUCTS ARE BEING RECALLED AT THIS TIME.HEALTH CANADA- NON-COMPLIANT RATING DOES NOT NECESSARILY INDICATE A PRODUCT SAFETY CONCERN.  全文

EMA Updates Risk Calculation From Valsartan Medicines With NDMA
2018年 9月 13日 星期四 17:13 BJT 

Sept 13 (Reuters) - European Medicines Agency (EMA)::UPDATED RISK CALCULATION FROM VALSARTAN MEDICINES WITH NDMA, TAKING INTO ACCOUNT RESULTS FROM LATEST TESTS FROM ZHEJIANG HUAHAI.SEES LIFE-TIME RISK OF CANCER TO BE 1 IN 5,000 FOR ADULT WHO TOOK AFFECTED VALSARTAN AT HIGHEST DOSE EVERY DAY FROM JULY 2012 - JULY 2018.CANCER RISK LOWER FOR PATIENTS WHO TOOK VALSARTAN MADE BY ZHEJIANG TIANYU, WHICH HAD SMALLER AMOUNTS OF NDMA VERSUS ZHEJIANG HUAHAI'S DRUG.  全文

Zhejiang Huahai Pharmaceutical's 6-Month Net Profit Down 22.4 Pct Y/Y
2018年 8月 24日 星期五 19:12 BJT 

Aug 24 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS 6-MONTH NET PROFIT DOWN 22.4 PERCENT Y/Y.  全文

Zhejiang Huahai Pharmaceutical says 2017 dividend payment
2018年 3月 29日 星期四 14:51 BJT 

March 29(Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says it plans to pay cash dividend of 2 yuan per 10 shares (before tax) and use additional paid-in capital to distribute 2 new shares for every 10 shares to shareholders for 2017.  全文

Zhejiang Huahai Pharmaceutical's Preliminary 2017 Net Profit Up 26.45 Pct Y/Y
2018年 2月 7日 星期三 17:26 BJT 

Feb 7 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>::SAYS PRELIM 2017 NET PROFIT UP 26.45 PERCENT Y/Y AT 633.29 MILLION YUAN ($101.16 million).  全文

Zhejiang Huahai Pharmaceutical passes U.S. FDA approval
2017年 10月 13日 星期五 20:17 BJT 

Oct 13(Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says it received approval for a kind of tablet, which is used for treatment of chronic hepatitis B, from U.S. Food and Drug Administration .Says it will be able to sell the tablet in the United States after receiving the FDA approval.  全文

Zhejiang Huahai Pharmaceutical passes FDA approval
2017年 9月 28日 星期四 11:07 BJT 

Sept 28 (Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:* Says it received approval for its production base of API from U.S Food and Drug Administration .  全文

Zhejiang Huahai Pharmaceutical to use $30 mln to acquire shares of Eutilex
2017年 9月 5日 星期二 16:11 BJT 

Sept 5(Reuters) - Zhejiang Huahai Pharmaceutical Co Ltd <600521.SS>:Says co signs agreement to invest $30 million in Eutilex Co.,Ltd, which is mainly engaged in R&D of T cell therapy and antibody therapy products .Says co will hold 18.8 percent stake (1.2 million shares) in Eutilex after investment, up from 0 percent .Says Eutilex plans to grant the co an exclusive right in China regarding EU101 and co will pay up to $8.5 million to Eutilex via upfront and milestones payments.  全文